Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2009-03-31
2009-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trem-1 and Ultraviolet Radiation-induced Immune Suppression
NCT05020496
Effect of RANKL Inhibition on UV-induced Immunosuppression
NCT01978483
Histologic Response to UVA and UVB Exposure During the Use of Sunscreen
NCT01892150
Physiopathological Study and Pharmacological Modulation of Cutaneous Atrophy's Markers Induced by Glucocorticoids
NCT00709579
Study to Test Genetic Alterations Among Different Dermoscopic Types of Melanocytic Nevi.
NCT00422448
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Until recently, the genotoxic effects of UV-A radiation, were poorly identified, in particular their capacity to lead to the dimerization of pyrimidine bases .
It is well known that the response to UV-A and UV-B radiations is different depending on the cutaneous phototype.
Thus, the aim of this study is to determine the correlation between cutaneous phototype and the quantity and nature (CPD or oxidative lesions) of damage caused to cutaneous DNA after an ex-vivo exposure to UV-A and UV-B radiations.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
phototype 2
Volunteers with cutaneous phototype 2
UVA and UVB irradiation
* 4 cutaneous biopsies for Ex-vivo irradiation
* Determination of the minimal erythemic dose of UVA and UVB for each volunteer
phototype 4
Volunteers with cutaneous phototype 4
UVA and UVB irradiation
* 4 cutaneous biopsies for Ex-vivo irradiation
* Determination of the minimal erythemic dose of UVA and UVB for each volunteer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
UVA and UVB irradiation
* 4 cutaneous biopsies for Ex-vivo irradiation
* Determination of the minimal erythemic dose of UVA and UVB for each volunteer
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Between 18 and 35 years old,
* Healthy volunteers,
* Cutaneous phototype 2 or 4 according to the Fitzpatrick classification,
* Affiliation to the French Social Security.
Exclusion Criteria
* Active smoking or stopped since less than one year,
* Dermatological pathology or treatment contra-indicating cutaneous irradiation and skin biopsies,
* Any chronic pathology susceptible to interfere with the evaluations related to the protocol,
* Allergy to local anaesthetics,
* Volunteers who take drugs and/or food complements acting on oxidative stress in the 8 weeks preceding inclusion,
* Volunteers who have take paracetamol or aspirin within 7 days prior to the inclusion visit,
* Subject in exclusion period for another biomedical research study,
* Subject having exceeded the threshold of annual compensation for biomedical research.
18 Years
35 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Commissariat A L'energie Atomique
OTHER_GOV
University Hospital, Grenoble
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University Hospital Grenoble
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean-Claude BEANI, Pr
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Grenoble
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre d'investigation Clinique ,University Hospital Grenoble
Grenoble, , France
Department of Dermatology, University Hospital Grenoble
Grenoble, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Brash DE. Sunlight and the onset of skin cancer. Trends Genet. 1997 Oct;13(10):410-4. doi: 10.1016/s0168-9525(97)01246-8.
Melnikova VO, Ananthaswamy HN. Cellular and molecular events leading to the development of skin cancer. Mutat Res. 2005 Apr 1;571(1-2):91-106. doi: 10.1016/j.mrfmmm.2004.11.015.
Cadet J, Sage E, Douki T. Ultraviolet radiation-mediated damage to cellular DNA. Mutat Res. 2005 Apr 1;571(1-2):3-17. doi: 10.1016/j.mrfmmm.2004.09.012. Epub 2005 Jan 26.
Douki T, Reynaud-Angelin A, Cadet J, Sage E. Bipyrimidine photoproducts rather than oxidative lesions are the main type of DNA damage involved in the genotoxic effect of solar UVA radiation. Biochemistry. 2003 Aug 5;42(30):9221-6. doi: 10.1021/bi034593c.
Dumaz N, Drougard C, Sarasin A, Daya-Grosjean L. Specific UV-induced mutation spectrum in the p53 gene of skin tumors from DNA-repair-deficient xeroderma pigmentosum patients. Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10529-33. doi: 10.1073/pnas.90.22.10529.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DCIC 08 13
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.